Effect of the hepatokine Tsukushi on HDL and reverse cholesterol transport
Journal of Lipid Research · 2026
DOI: 10.1016/j.jlr.2026.101110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2026. Verfasst von Sum Lam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Liver, Cholesterol, HDL, Cholesterol. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Hong Kong.
Abstract (Originalsprache)
Tsukushi (TSK), a secreted protein of the leucine-rich proteoglycan family that functions as a hepatokine, is upregulated in liver diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD). Clinical studies have shown that serum TSK levels inversely correlate with plasma HDL cholesterol (HDL-C) in MASLD. This study investigated the impact of hepatic TSK overexpression on reverse cholesterol transport (RCT) and HDL function. Golden Syrian hamsters were transduced with adeno-associated virus encoding TSK (AAV-TSK) and fed a standard chow diet. After 8 weeks, in vivo macrophage-to-feces RCT was assessed by intraperitoneal injection of tritium-labeled cholesterol-loaded macrophages, with serum, liver, and fecal samples collected at 48 h. Ex vivo HDL cholesterol efflux capacity was measured using RAW264.7 macrophages. Hepatic lipid metabolism gene expression, serum apolipoprotein A-I (apoA-I) levels, and lecithin-cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activities were quantified. TSK overexpression did not induce hepatic steatosis. At week 8, serum HDL-C and HDL-phospholipids were reduced (P < 0.05) in AAV-TSK hamsters compared with controls, whereas LCAT and CETP activities were similar. Ex vivo cholesterol efflux capacity of HDL was significantly diminished (P < 0.05). RCT was impaired, with tritium tracer reduced by 34.2% in HDL (P < 0.01) and 27.6% in liver (P < 0.05). Hepatic cholesterol content was reduced (P < 0.05), but triglyceride levels remained unchanged. Both hepatic and circulating apoA-I levels were significantly reduced (P < 0.05). TSK overexpression impaired RCT by suppressing apoA-I expression, reducing HDL-mediated cholesterol efflux, and thereby attenuating macrophage-to-feces cholesterol transport.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
- Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China. Electronic address: kcbtan@hku.hk.
Förderung
- The University of Hong Kong
Zitieren
APA
Lam, S., Wong, Y., Shiu, S. W., Lee, C. H., & Tan, K. C. (2026). Effect of the hepatokine Tsukushi on HDL and reverse cholesterol transport. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2026.101110
Vancouver
Lam S, Wong Y, Shiu SW, Lee CH, Tan KC. Effect of the hepatokine Tsukushi on HDL and reverse cholesterol transport. Journal of Lipid Research. 2026. doi:10.1016/j.jlr.2026.101110
BibTeX
@article{Lam2026,
author = {Lam, Sum and Wong, Ying and Shiu, Sammy Wing-Ming and Lee, Chi-Ho and Tan, Kathryn Choon-Beng},
title = {Effect of the hepatokine Tsukushi on HDL and reverse cholesterol transport},
journal = {Journal of Lipid Research},
year = {2026},
doi = {10.1016/j.jlr.2026.101110}
}
EUVIMED